Page last updated: 2024-11-04

temozolomide and Leukemia

temozolomide has been researched along with Leukemia in 11 studies

Leukemia: A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)

Research Excerpts

ExcerptRelevanceReference
"To determine the tolerability, pharmacokinetics, and mechanisms of temozolomide resistance in children with relapsed or refractory leukemia."9.12Phase I pharmacokinetic and pharmacodynamic study of temozolomide in pediatric patients with refractory or recurrent leukemia: a Children's Oncology Group Study. ( Adamson, PC; Berg, SL; Blaney, SM; Delaney, SM; Dolan, ME; Hedge, M; Horton, TM; Ingle, AM; Thompson, PA; Weiss, HL; Wu, MF, 2007)
"To determine the tolerability, pharmacokinetics, and mechanisms of temozolomide resistance in children with relapsed or refractory leukemia."5.12Phase I pharmacokinetic and pharmacodynamic study of temozolomide in pediatric patients with refractory or recurrent leukemia: a Children's Oncology Group Study. ( Adamson, PC; Berg, SL; Blaney, SM; Delaney, SM; Dolan, ME; Hedge, M; Horton, TM; Ingle, AM; Thompson, PA; Weiss, HL; Wu, MF, 2007)
" A pilot clinical study indicates that dacarbazine can induce a marked decrease of leukemic blasts in patients affected by acute myelogenous leukemia (AML) with low pretreatment levels of OGAT activity."5.08Cisplatin increases sensitivity of human leukemic blasts to triazene compounds. ( Bonmassar, E; Caravita, T; D'Atri, S; Franchi, A; Graziani, G; Papa, G; Piccioni, D, 1995)
" We report a 44-year-old woman with t-MDS (refractory anemia with excess blasts) following treatment of recurrent anaplastic astrocytoma with temozolomide (TMZ)."4.82Treatment-related myelodysplastic syndrome after temozolomide for recurrent high-grade glioma. ( Chang, MC; Chiang, MF; Hsieh, RK; Su, YW, 2005)
"treatment with Lomeguatrib (to suppress MGMT activity) and Temozolomide (to kill sensitive blasts and to presumably induce CX in resistant leukaemic cells); (b) immune response recovery phase using interleukin-2 (to possibly restore an immune response and take advantage of the hypothetical, triazene-induced CX)."1.34Novel role of triazenes in haematological malignancies: pilot study of Temozolomide, Lomeguatrib and IL-2 in the chemo-immunotherapy of acute leukaemia. ( Alvino, E; Amadori, S; Bonmassar, E; Buccisano, F; Caporaso, P; D'Atri, S; Garbin, A; Marchesi, F; Tirindelli, MC; Toppo, L; Tortorelli, G; Turriziani, M; Venditti, A, 2007)

Research

Studies (11)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's4 (36.36)18.2507
2000's5 (45.45)29.6817
2010's2 (18.18)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Horton, TM2
Jenkins, G1
Pati, D1
Zhang, L1
Dolan, ME2
Ribes-Zamora, A1
Bertuch, AA1
Blaney, SM2
Delaney, SL1
Hegde, M1
Berg, SL2
Rizzieri, D1
LoRusso, S1
Tse, W1
Khan, K1
Advani, A1
Moore, J1
Karsten, V1
Cahill, A1
Gerson, SL1
Cipak, L1
Su, YW1
Chang, MC1
Chiang, MF1
Hsieh, RK1
Katsoulas, A1
Rachid, Z1
Brahimi, F1
McNamee, J1
Jean-Claude, BJ1
Caporaso, P1
Turriziani, M2
Venditti, A1
Marchesi, F1
Buccisano, F1
Tirindelli, MC1
Alvino, E1
Garbin, A1
Tortorelli, G1
Toppo, L1
Bonmassar, E5
D'Atri, S4
Amadori, S1
Thompson, PA1
Adamson, PC1
Ingle, AM1
Delaney, SM1
Hedge, M1
Weiss, HL1
Wu, MF1
Tentori, L3
Graziani, G4
Gilberti, S1
Lacal, PM2
Piccioni, D1
Papa, G1
Caravita, T1
Franchi, A1
Orlando, L1
Benincasa, E1
Faraoni, I1
Franco, D1
Serafino, A1
Levati, L1
Roy, R1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase I Study Of Cloretazine™ (VNP40101M) And Temozolomide In Patients With Hematologic Malignancies[NCT00098436]Phase 125 participants (Anticipated)Interventional2004-09-30Completed
A Phase I Trial Of Temozolomide In Pediatric Patients With Refractory/Recurrent Leukemias[NCT00083070]Phase 116 participants (Actual)Interventional2004-03-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

1 review available for temozolomide and Leukemia

ArticleYear
Treatment-related myelodysplastic syndrome after temozolomide for recurrent high-grade glioma.
    Journal of neuro-oncology, 2005, Volume: 71, Issue:3

    Topics: Acute Disease; Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Chromosomes,

2005

Trials

3 trials available for temozolomide and Leukemia

ArticleYear
Phase I study of temozolomide and laromustine (VNP40101M) in patients with relapsed or refractory leukemia.
    Clinical lymphoma, myeloma & leukemia, 2010, Volume: 10, Issue:3

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Histor

2010
Phase I pharmacokinetic and pharmacodynamic study of temozolomide in pediatric patients with refractory or recurrent leukemia: a Children's Oncology Group Study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Nov-01, Volume: 25, Issue:31

    Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Child; Child, Preschool; Dacarbazine; DNA Modi

2007
Cisplatin increases sensitivity of human leukemic blasts to triazene compounds.
    Journal of chemotherapy (Florence, Italy), 1995, Volume: 7, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cisplatin; Dacarbazine; D

1995

Other Studies

7 other studies available for temozolomide and Leukemia

ArticleYear
Poly(ADP-ribose) polymerase inhibitor ABT-888 potentiates the cytotoxic activity of temozolomide in leukemia cells: influence of mismatch repair status and O6-methylguanine-DNA methyltransferase activity.
    Molecular cancer therapeutics, 2009, Volume: 8, Issue:8

    Topics: Antineoplastic Agents, Alkylating; Benzimidazoles; Cell Line, Tumor; Dacarbazine; DNA Mismatch Repai

2009
Novel nonclassical antifolate, 2-[N-(2´-Hydroxyethyl)amino]methyl-3H-quinazolin-4-one, with a potent antineoplastic activity toward leukemia cells.
    Neoplasma, 2012, Volume: 59, Issue:6

    Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Survival; Cisplatin; Dacarbazine; Female

2012
Engineering 3-alkyltriazenes to block bcr-abl kinase: a novel strategy for the therapy of advanced bcr-abl expressing leukemias.
    Leukemia research, 2005, Volume: 29, Issue:6

    Topics: Apoptosis; Cell Line, Tumor; Cell Survival; Culture Media; Dacarbazine; DNA Damage; Dose-Response Re

2005
Novel role of triazenes in haematological malignancies: pilot study of Temozolomide, Lomeguatrib and IL-2 in the chemo-immunotherapy of acute leukaemia.
    DNA repair, 2007, Aug-01, Volume: 6, Issue:8

    Topics: Animals; Antineoplastic Agents, Alkylating; Combined Modality Therapy; Dacarbazine; DNA Methylation;

2007
Triazene compounds induce apoptosis in O6-alkylguanine-DNA alkyltransferase deficient leukemia cell lines.
    Leukemia, 1995, Volume: 9, Issue:11

    Topics: Antineoplastic Agents, Alkylating; Apoptosis; Dacarbazine; Gene Expression; Humans; Leukemia; Methyl

1995
Inhibition of O6-alkylguanine DNA-alkyltransferase or poly(ADP-ribose) polymerase increases susceptibility of leukemic cells to apoptosis induced by temozolomide.
    Molecular pharmacology, 1997, Volume: 52, Issue:2

    Topics: Antineoplastic Agents, Alkylating; Apoptosis; Dacarbazine; DNA Fragmentation; DNA Methylation; DNA R

1997
Treatment with temozolomide and poly(ADP-ribose) polymerase inhibitors induces early apoptosis and increases base excision repair gene transcripts in leukemic cells resistant to triazene compounds.
    Leukemia, 1999, Volume: 13, Issue:6

    Topics: Antineoplastic Agents, Alkylating; Apoptosis; Benzamides; Dacarbazine; DNA Glycosylases; DNA Ligases

1999